{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:58:00Z","timestamp":1787065080229,"version":"build-2736575974"},"reference-count":25,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T00:00:00Z","timestamp":1729900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304629"],"award-info":[{"award-number":["82304629"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Andrology"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Growing evidence indicates that paternal condition significantly influences pregnancy outcomes and offspring health. However, assessing the safety of paternal drug exposure via randomized controlled trials poses ethical challenges, and relevant clinical studies consume a lot of resources to evaluate only a few drugs. Currently, safety data on paternal drug exposure are scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate the impact of paternal drug exposure on fertility, pregnancy outcomes, and offspring health.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Data from the FDA adverse event reporting system (FAERS) were analyzed (2010\u20132022). Disproportionality analyses were used to identify signals of each drug\u2010adverse event pair associated with paternal drug exposure in a different hierarchical manner.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Out of the 16,180,533 reports, 3210 were related to paternal exposure, encompassing 7808 concomitant adverse events. Drugs used to treat rheumatoid arthritis, cancer, and infections were primary sources of paternal exposure. Analysis identified 115 signals concerning reproductive health. Notably, the signals of diazepam\u2010small for dates baby and finasteride\u2010cryptorchidism were particularly significant (reporting odds ratio, ROR\u00a0&gt;\u00a0800,\n                      <jats:italic>N<\/jats:italic>\n                      \u00a0&gt;\u00a010). Moreover, spontaneous abortion signals occur frequently in biologics for the treatment of immune inflammation; the use of immunosuppressive drugs was associated with the highest number of congenital anomalies, with the strongest signals for belatacept\u2010skeletal dysplasia, and tacrolimus\u2010talipes. Only mycophenolic acid, estrogen and imatinib have signals on male fertility. Anti\u2010tumor agents had high numbers of each reproductive toxicity, with the highest values of trisomy 13 signals associated with etoposide and cisplatin.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This is the first research to fully assess the safety of paternal exposure to the majority of medications in terms of reproduction. Clinical and scientific researchers should pay close attention to the list of risk medications included in this study, particularly the following association combinations: biologics used to treat inflammatory diseases\u2014abortion, diazepam\u2014small for date baby, finasteride\u2014cryptorchidism, etoposide and cisplatin\u201013 trisomy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/andr.13790","type":"journal-article","created":{"date-parts":[[2024,10,27]],"date-time":"2024-10-27T01:54:16Z","timestamp":1729994056000},"page":"1420-1431","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety concerns of paternal drug exposure on fertility, pregnancy and offspring: An analysis based on the FDA adverse event reporting system"],"prefix":"10.1111","volume":"13","author":[{"given":"Yanbin","family":"Zeng","sequence":"first","affiliation":[{"name":"Department of Pharmacy Women and Children's Hospital, School of Medicine, Xiamen University  Xiamen China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanlong","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Women and Children's Hospital, School of Medicine, Xiamen University  Xiamen China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1720-8882","authenticated-orcid":false,"given":"Wei","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Women and Children's Hospital, School of Medicine, Xiamen University  Xiamen China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,10,26]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2019.12.026"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41437-018-0111-0"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2020.01.032"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmad006"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.7326\/M21-4389"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.405"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbab347"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2920"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.03.020"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38919"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296\u2010020\u201004518\u20103"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab910"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04426.x"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(23)00148-7"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/cimb43020062"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2017.68528"},{"key":"e_1_2_10_18_1","unstructured":"17. U.S. Food and Drug Administration. Drug Approval Package: Arcalyst (Rilonacept) NDA #125249. Accessed Feb 26 2024.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2008\/125249s000TOC.cfm"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-44374-2"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.03.030"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-019-00509-2"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1159\/000114274"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12226"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2047-2927.2014.00185.x"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1095\/biolreprod.115.137802"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2016.11.015"}],"container-title":["Andrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/andr.13790","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T11:03:36Z","timestamp":1755774216000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/andr.13790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,26]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1111\/andr.13790"],"URL":"https:\/\/doi.org\/10.1111\/andr.13790","archive":["Portico"],"relation":{},"ISSN":["2047-2919","2047-2927"],"issn-type":[{"value":"2047-2919","type":"print"},{"value":"2047-2927","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,26]]},"assertion":[{"value":"2024-05-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}